Images List Premium Download Classic

C Syndrome

C Syndrome-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Chemical compounds and use thereof for improving muscular quality
Universite Paris 6 Pierre Et Marie Curie
August 10, 2017 - N°20170226151

Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical ...
N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
Universiteit Leiden
August 10, 2017 - N°20170226058

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency ...
Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes
Illinois Institute Of Technology
August 03, 2017 - N°20170216409

The disclosure provides methods of preventing or treating metabolic syndrome in a subject by administering an effective amount of an inhibitor of laminin α4 expression, laminin α4 activity, or both.
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Roasted laurina coffee, method for its preparation, and use for preventing metabolic syndrome
Illycaffe' S.p.a.
August 03, 2017 - N°20170216387

A roasted coffee of coffea arabica var. Laurina a powder of which comprises from 5. 0 to 10. 0 mg per gram of powder (mg/g) trigonelline and from 3. 0 to 8. 0 mg/g mono-caffeoylquinic acids (3-caffeoylquinic acid, 4-caffeoylquinic acid and 5-caffeoylquinic acid), the invention also relating to a beverage prepared with such roasted coffee, a method for the preparation and a use of such roasted ...
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
Illycaffe' S.p.a.
July 27, 2017 - N°20170209539

In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, ...
Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
H. Lee Moffitt Cancer Center And Research Institute, Inc.
July 27, 2017 - N°20170209434

Disclosed are methods for treating a meylodysplastic syndrome (mds) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2a (pp2a) inhibitor.
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cobalt porphyrins for the treatment of blood-related disorders
Uniwersytet Jagiellonski
July 13, 2017 - N°20170196882

The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem ...
Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
Thymon, Llc
July 06, 2017 - N°20170190768

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf. A pharmaceutical composition contains one or more antibodies or ligands: (a) an antibody or ligand that specifically binds the tnf monomer-specific epitope having the sequence psdkpvah ...
Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity ...
Consejo Superior De Investigaciones Cientificas
July 06, 2017 - N°20170189456

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of bacteroides uniforms, preferably cect 7771, or of the ...
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
Boehringer Ingelheim International Gmbh
July 06, 2017 - N°20170189437

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, ...
Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
Merck Patent Gmbh
July 06, 2017 - N°20170189354

The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of type ii diabetes mellitus, the metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of ...
Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
Amgen Inc.
June 29, 2017 - N°20170183412

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing b-klotho, and or fgf21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-klotho and at least one of (i) fgfr1c, (ii) fgfr2c and (iii) fgfr3c. In some embodiments the antigen ...
N-hydroxy bicyclic hydantoin carbamates as tools for indetification of serine hydrolase targets
The Scripps Research Institute
June 29, 2017 - N°20170183353

Provided herein are n-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases. Furthermore, the subject compounds and compositions are useful for the treatment of one or more of cancer, pain, diabetes, obesity/metabolic syndrome, epilepsy, traumatic brain injury, and inflammation.
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods ...
Volant Holdings Gmbh
June 22, 2017 - N°20170173060

In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a) confirming that the subject suffers from or is at risk for suffering from organ and/or tissue damage associated with a glucose supply side ...
Methods for treating visceral fat conditions
Orexigen Therapeutics, Inc.
June 22, 2017 - N°20170172999

Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
Berg Llc
June 15, 2017 - N°20170166891

The invention provides methods of treatment of metabolic syndrome with hsp90 inhibitors, particularly hsp90β inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using hsp90, particularly hsp90β, expression and activity level.
Modulation of oxidative stress, inflammation, and impaired insulin sensitivity with grape seed extract
Illinois Institute Of Technology
June 15, 2017 - N°20170165312

Method for modulating oxidative stress, inflammation, and impaired insulin sensitivity in a subject by using a grape seed extract, the method being useful in modulating post-prandial oxidative stress, inflammation, and impaired insulin sensitivity in patients suffering from metabolic syndrome (mets). The method comprising administering a therapeutically effective amount of a grape seed extract and a pharmaceutically acceptable excipient. The grape ...
Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
Illinois Institute Of Technology
June 15, 2017 - N°20170165211

The present invention relates to a modified taurine, and a pharmaceutical composition for preventing or treating metabolic disease or a food composition, which contains the modified taurine as an active ingredient. More specifically, the modified taurine of the present invention has physical properties different from those of existing taurine, and has significant effects on the prevention and treatment of metabolic ...
Novel lactic acid bacteria and use thereof
New Bellus Enterprises Co., Ltd.
June 08, 2017 - N°20170157183

The present invention discloses novel lactic acid bacteria, which are isolated lactococcus lactis subsp. Lactis ll358 and isolated lactobacillus salivarius ls159 respectively. By administering the novel lactic acid bacteria of the present invention, renal injury, metabolic syndrome, hyperuricemia, hypocalcemia, and other disorders can be effectively ameliorated or treated.
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i
Boehringer Ingelheim International Gmbh
June 08, 2017 - N°20170157159

The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
Boehringer Ingelheim International Gmbh
June 08, 2017 - N°20170157158

The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).
Loading